Merit Medical Eyes Next Growth Plan as Margins, Portfolio Review Take Center Stage

Merit Medical is completing its current long-range plan while developing a new three-year strategy, including a review of performance metrics and potential targeted portfolio changes rather than broad divestitures. Margin expansion remains broad-based, with 850 basis points already achieved and potentially 950 basis points by year-end through pricing, mix, manufacturing efficiency, automation, acquisitions and logistics improvements. The company raised its outlook after 9% second-quarter organic growth, now forecasting 6.9%–7.5% organic growth and adjusted EPS of $4.25–$4.35; endoscopy, OEM operations and the OneMark acquisition are key growth areas.

Merit Medical Systems NASDAQ: MMSI is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event. Parra said the company remains “hyper-focused” on executing its current CGI plan and does not want to “drop the football on the one-yard line.” He said the company is working with CEO Martha on the next three-year plan after she spent time visiting company sites and participating in the strategic-planning process.

While Parra did not provide new targets, he said Merit is evaluating whether the core metrics used in its past long-range plans remain the right measures for the next plan. Those prior targets included organic revenue growth, operating-margin expansion and cumulative free cash flow. The company has previously presented new plans either in November before a program begins or alongside its fourth-quarter results, though Parra said management is also considering whether to provide the update sooner.

Merit is reviewing its portfolio platform by platform to determine where it is performing well, where it needs improvement and which assets may not fit the company’s strategic call points, Parra said. He described the process as “strategic and surgical,” rather than one involving large divestitures. The company has assembled businesses across oncology, endoscopy, renal therapies and access through acquisitions, Parra said. While he characterized the portfolio as being in attractive markets and procedures, he said there could be opportunities to prune smaller assets that sit outside Merit's primary call points. Parra cited the company’s divestiture of DualCap as an example of the type of smaller, targeted action management could consider. He said it was too early to determine whether further changes would extend beyond SKU rationalization or involve additional product-line sales.

Parra said Merit has delivered 850 basis points of operating-margin improvement and could approach 950 basis points if it reaches the high end of its current-year guidance. He said the company expects further gains to come from continuing to address a broad range of factors, including pricing, sales mix, new product introductions, acquisitions, manufacturing efficiency, automation, lower-cost production transfers, raw materials, scale and logistics. Rather than relying on a single initiative, Parra said Merit aims to prevent gains in one area from being offset by weaker execution elsewhere. He described the company as being “perpetually” in the seventh inning of margin work: past the heaviest lifting but still able to apply lessons from its prior transformation efforts consistently. On capital allocation, Parra said Merit remains interested in tuck-in acquisitions across its existing platforms, depending on available opportunities.